ANEB on OTC
Anebulo Pharmaceuticals, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
-$8.5MNet income, fiscal 20252
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-72.8%Return on equity2
Financial statements
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Research and development | $2.3M4 | $3.0M5 | $5.6M6 | $3.5M2 | $4.3M2 | |
| Operating income | -$3.6M4 | -$6.8M5 | -$11.8M6 | -$8.3M2 | -$9.2M2 | |
| Interest | $11.8K4 | $200.0K2 | $400.0K2 | |||
| Net income | -$30.3M4 | -$6.8M5 | -$11.7M6 | -$8.2M2 | -$8.5M2 | |
| Earnings per share | -$2.834 | $0.295 | -$0.476 | -$0.322 | -$0.252 | |
| Earnings per share (diluted) | $0.295 | -$0.476 | -$0.322 | -$0.252 |
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash | $11.2M6 | $3.1M2 | $11.6M2 | |||
| Current assets | $11.7M6 | $3.5M2 | $12.0M2 | |||
| Total assets | $3.0M9 | $21.7M4 | $15.6M5 | $11.7M6 | $4.1M2 | $12.1M2 |
| Total liabilities | $223.9K9 | $241.6K4 | $512.5K5 | $1.1M6 | $260.6K2 | $487.7K2 |
| Shareholders’ equity | -$171.1K4 | $21.4M5 | $15.1M6 | $10.6M2 | $3.8M2 | $11.7M2 |
| Shares outstanding | 12.0M shares9 | 23.3M shares9 | 23.4M shares4 | 25.6M shares5 | 25.9M shares6 | 41.1M shares2 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Recent filings
- Mar 2, 202615-12G
- Feb 17, 202625
- Feb 13, 2026SCHEDULE 13G/A
- Feb 12, 20268-K
- Feb 12, 202610-Q
- Feb 6, 20268-K
- Jan 29, 20268-K
- Jan 29, 2026SC 13E3/A SC TO-I/A
- Jan 27, 20268-K
- Jan 27, 2026SC 13E3/A SC TO-I/A
- Jan 8, 2026SC 13E3/A SC TO-I/A
- Jan 8, 2026CORRESP
- Dec 31, 2025UPLOAD
- Dec 22, 20258-K
- Dec 22, 2025SC TO-I
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9